Single agents in cancer chemotherapy
Author(s)
Bibliographic Information
Single agents in cancer chemotherapy
IFI/Plenum, 1970
Available at 2 libraries
  Aomori
  Iwate
  Miyagi
  Akita
  Yamagata
  Fukushima
  Ibaraki
  Tochigi
  Gunma
  Saitama
  Chiba
  Tokyo
  Kanagawa
  Niigata
  Toyama
  Ishikawa
  Fukui
  Yamanashi
  Nagano
  Gifu
  Shizuoka
  Aichi
  Mie
  Shiga
  Kyoto
  Osaka
  Hyogo
  Nara
  Wakayama
  Tottori
  Shimane
  Okayama
  Hiroshima
  Yamaguchi
  Tokushima
  Kagawa
  Ehime
  Kochi
  Fukuoka
  Saga
  Nagasaki
  Kumamoto
  Oita
  Miyazaki
  Kagoshima
  Okinawa
  Korea
  China
  Thailand
  United Kingdom
  Germany
  Switzerland
  France
  Belgium
  Netherlands
  Sweden
  Norway
  United States of America
Note
Includes bibliographies and index
Description and Table of Contents
Description
The clinical trials program of anti-tumor drugs was started by the National Cancer Institute in 1955. In the past 15 years, this national network has collected a large body of data on all of the recognized anti-tumor drugs as well as upon new, experimentally promising agents. While the most important of these studies have been published, there has remained a wealth of data not generally available to the scientific community. Drs. Carter and Livingston have not only succeeded in organ~z~ng this large corpus, they have in addition analyzed and interpreted the clinical data in a way that will be highly useful for years to come. From a perusal of this volume it becomes apparent that some drugs are more active against certain tumors than had been realized; that the evidence for the activity of certain drugs against specific tumors is sometimes tenuous; surprisingly, that some highly active agents have never been tried against some of the fairly common tumors. Their monumental work has provided not only access to the hard data, it has also shown the need for research to fill in important gaps in our knowledge.
The authors and the IFI/Plenum Press are to be congratulated for this useful and important work. C. Gordon Zubrod, M. D. Scientific Director for Chemotherapy National Cancer Institute National Institutes of Health Bethesda, Maryland v Acknowledgment The authors wish to thank Dr. C. Gordon Zubrod and Dr.
Table of Contents
Mechlorethamine.- Cyclophosphamide.- Chlorambucil.- Melphalan.- Busulfan.- Methotrexate.- 6-Mercaptopurine.- 5-Fluorouracil.- Cytosine Arabinoside.- Hydroxyurea.- Actinomycin D.- Mithramycin.- Vinblastine.- Vincristine.- Procarbazine.- Prednisone and Prednisolone.- Investigational Agents.- 1,3-Bis(2-chloroethyl)-l-nitrosourea (BCNU).- Daunorubicin (Daunomycin, rubidomycin).- Dimethyl triazeno imidazole carboxamide.- Streptozotocin.- Dibromomannitol.- Methyl-GAG.- Mitomycin C.- Streptonigrin.- L-asparaginase.
by "Nielsen BookData"